Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (455)	3/7/1999 9:30:00 PM
From: mike head	Respond to of 613

Scott. Interesting--- Just been doing my own review of AXPH. I view the spin out/partnership with PPD as entirely positive- if long term! For an outfit which wants to play big-time in pharmacogenomics, hooking up with a large CRO certainly seems to make sense. Hope others will contribute here. Pax et Bonum, mch

To: Scott H. Davis who wrote (455)	3/7/1999 10:30:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 613

Go figure! Look at most of the biotechs and the "beating" they've taken in the past few weeks. With all the expected "good" news coming soon for Xoma, it is selling off. Look at GLGC, nothing but positive news and the stock is in a "swan dive". Then there is LGND. Should I gone on with the list.(:<<<<<<)Even my darling little ATRX, who reported their first full year of earnings and they were down over 2 points last week. Ouch! Family and I are headed to California tomorrow and with the luck I've had, it is a good thing I paid for the tickets in advance. Plus, it will probably rain all week while we are there.(:<<)